Robert E. Bristow, MD
Professor and Division Director
University of California, Irvine
101 The City Dr. S
Bldg 56, Rm 800
Irvine,
CA
USA
92868
Biographical Sketch: Dr. Bristow holds the Philip J. DiSaia Prestigious Chair and is Professor and Director of Gynecologic Oncology at the University of California, Irvine School of Medicine and Medical Center. Dr. Bristow’s clinical and research interests include cytoreductive surgery for advanced-stage and recurrent ovarian cancer, health care outcomes, and patterns of gynecologic cancer care. He is an academic gynecologic oncologist and has been extensively published in the peer-reviewed literature on the topic of ovarian cancer outcomes. He has previously presented plenary sessions at the SGO Annual Meeting including the Hugh Barber Lecture."
Papers:
5
Correlation between surgeon's assessment of residual disease and findings on postoperative pre-treatment computed tomography scan in women with advanced stage ovarian cancer reported to have undergone optimal cytoreduction: an NRG Oncology/GOG study
92
Ovarian cancer patients selected for neoadjuvant chemotherapy vs. primary debulking surgery are not similar: a National Cancer Data Base study
93
Surgical complexity score and oncologic outcomes following optimal or complete cytoreductive surgery for ovarian, fallopian tube and primary peritoneal cancers
107
Analysis of disparities in advanced ovarian cancer treatment and survival in the Medicare population using propensity score matching
131
Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer
206
Endometrial cancer survivor perspectives on weight loss and lifestyle modifications: a Uterine Cancer Action Network study
268
Primary debulking surgery and neo-adjuvant chemotherapy in the Medicare population: an analysis of cost of care
382
Under-utilization of minimally invasive surgery in the management of endometrial cancer: a Healthcare Cost and Utilization Project-National Inpatient Sample study (HCUP-NIS)
463
Refusal of recommend chemotherapy for ovarian cancer: risk factors and outcomes, a National Cancer Database study
466
Cost effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
469
Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention
Impact of NCI Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival
Pro/Con Debate